

Meibomian Gland Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/M33D2A1D29D2EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: M33D2A1D29D2EN

Abstracts

The 7 major meibomian gland dysfunction markets reached a value of US\$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.07% during 2024-2034.

The meibomian gland dysfunction market has been comprehensively analyzed in IMARC's new report titled "Meibomian Gland Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Meibomian gland dysfunction (MGD) refers to a set of diseases that can be either congenital or acquired and are connected by functional deviations of the meibomian glands. This condition develops when one of the several dozen small glands in the eyelids that contribute to the production of the oil layer in tears has a problem. The ailment can cause a change in the composition of the tear film, ocular surface disease, discomfort in the eyes and eyelids, and evaporative dry eye. Based on gland secretion, MGD can be classified as low or high delivery. There are no specific indications in the early stages, but as the condition progresses, the patients may experience less or poor-quality oil in the tear film, irritated, inflamed, and itchy eyelids, a feeling of sand or dust in the eye, stickiness or crusting, moments of blurred vision, burning sensations, etc. The diagnosis of this ailment is made by a review of underlying symptoms, medical history, and an initial clinical examination. Various other common procedures to confirm a diagnosis include Schirmer's test, mass spectrometry, interferometry, etc.

The rising cases of eye diseases, which cause damage and inflammation to the eyelids and cornea, are primarily driving the meibomian gland dysfunction market. Additionally, the increasing prevalence of various risk factors, such as hormonal changes, allergies, skin conditions, use of eye makeup, contact lens wear, etc., are further propelling the

market growth. Moreover, the widespread adoption of effective drugs, including antibiotics, steroids, omega-3 fatty acid supplements, etc., to help reduce indications associated with the ailment is acting as another significant growth-inducing factor. Apart from this, the rising usage of non-pharmacological interventions, such as warm compresses and massage therapy, since they can ease irritation and open clogged oil glands, is also augmenting the market growth. Furthermore, the escalating demand for non-contact meibography, owing to its numerous advantages over traditional meibography, including lesser time consumption, reduced risk of infection, and minimum patient discomfort, is creating a positive outlook for the market. Besides this, the increasing utilization of vector thermal pulsation system that delivers regulated amounts of pressure and heat to clear blockages in the meibomian glands for disease management is expected to drive the meibomian gland dysfunction market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the meibomian gland dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for meibomian gland dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the meibomian gland dysfunction market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the meibomian gland dysfunction market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the meibomian gland dysfunction market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current meibomian gland dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the meibomian gland dysfunction market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the meibomian gland dysfunction market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the meibomian gland dysfunction market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of meibomian gland dysfunction across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of meibomian gland dysfunction by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of meibomian gland dysfunction by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with meibomian gland dysfunction across the seven major markets?

What is the size of the meibomian gland dysfunction patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of meibomian gland dysfunction?

What will be the growth rate of patients across the seven major markets?

Meibomian Gland Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for meibomian gland dysfunction drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the meibomian gland dysfunction market?
What are the key regulatory events related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by status related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by phase related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by route of administration related to the meibomian gland dysfunction market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MEIBOMIAN GLAND DYSFUNCTION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MEIBOMIAN GLAND DYSFUNCTION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MEIBOMIAN GLAND DYSFUNCTION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 MEIBOMIAN GLAND DYSFUNCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MEIBOMIAN GLAND DYSFUNCTION - UNMET NEEDS

10 MEIBOMIAN GLAND DYSFUNCTION - KEY ENDPOINTS OF TREATMENT

11 MEIBOMIAN GLAND DYSFUNCTION - MARKETED PRODUCTS

- 11.1 List of Meibomian Gland Dysfunction Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 MEIBOMIAN GLAND DYSFUNCTION - PIPELINE DRUGS

12.1 List of Meibomian Gland Dysfunction Pipeline Drugs Across the Top 7 Markets

12.1.1 AZR MD 001 - Azura Ophthalmics

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 CBT008 - Cloudbreak therapeutics

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 CBT006 - Cloudbreak therapeutics

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. MEIBOMIAN GLAND DYSFUNCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MEIBOMIAN GLAND DYSFUNCTION – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 MEIBOMIAN GLAND DYSFUNCTION - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

- 15.2.1 Meibomian Gland Dysfunction - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Meibomian Gland Dysfunction - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Meibomian Gland Dysfunction - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Meibomian Gland Dysfunction - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Meibomian Gland Dysfunction - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Meibomian Gland Dysfunction - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Meibomian Gland Dysfunction - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Meibomian Gland Dysfunction - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Meibomian Gland Dysfunction - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview

16 MEIBOMIAN GLAND DYSFUNCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MEIBOMIAN GLAND DYSFUNCTION MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 MEIBOMIAN GLAND DYSFUNCTION MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Meibomian Gland Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M33D2A1D29D2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M33D2A1D29D2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

